192 related articles for article (PubMed ID: 23359554)
1. Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial.
Dudek D; Mehran R; Dziewierz A; Witzenbichler B; Brodie BR; Kornowski R; Fahy M; Lansky AJ; Rakowski T; Legutko J; Bryniarski L; Stone GW
Catheter Cardiovasc Interv; 2013 Nov; 82(6):869-77. PubMed ID: 23359554
[TBL] [Abstract][Full Text] [Related]
2. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
3. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
[TBL] [Abstract][Full Text] [Related]
4. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
6. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
8. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
10. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
[TBL] [Abstract][Full Text] [Related]
11. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
12. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
[TBL] [Abstract][Full Text] [Related]
15. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
16. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
18. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
19. Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI.
Brener SJ; Ertelt K; Mehran R; Genereux P; Xu K; Witzenbichler B; Brodie BR; Guagliumi G; Stone GW
Am Heart J; 2015 Feb; 169(2):242-8. PubMed ID: 25641533
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]